ATAI Stock Overview
A clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Atai Life Sciences N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.31 |
| 52 Week High | US$2.85 |
| 52 Week Low | US$1.03 |
| Beta | 0.81 |
| 11 Month Change | -17.61% |
| 3 Month Change | -21.08% |
| 1 Year Change | -17.09% |
| 33 Year Change | -91.78% |
| 5 Year Change | n/a |
| Change since IPO | -93.26% |
Recent News & Updates
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15
ATAI: Enormous Potential Upside But No Clarity Yet
May 27Recent updates
Is Atai Life Sciences (NASDAQ:ATAI) Using Debt In A Risky Way?
Jul 15ATAI: Enormous Potential Upside But No Clarity Yet
May 27Is Atai Life Sciences (NASDAQ:ATAI) Using Debt Sensibly?
Mar 02atai Life Sciences achieves positive results in phase 1 trial of kratom-derived drug
Oct 12Atai Life Sciences: Decentralized Drug Discovery Platform
Oct 06ATAI Life Sciences GAAP EPS of -$0.24 misses by $0.01
Aug 15We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Aug 07Atai Life Sciences: Leading But Early Stage Psychedelic Therapeutics Developer
Jul 07atai Life Sciences company Kures Therapeutics appoints Dr. Chad Beyer as CEO
Jun 30Atai Life Sciences N.V.: A First Take
Jun 02Atai Life Sciences And The Future Of Psychedelics For Mental Health
May 27We're Hopeful That Atai Life Sciences (NASDAQ:ATAI) Will Use Its Cash Wisely
Apr 22Shareholder Returns
| ATAI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 1.2% |
| 1Y | -17.1% | 19.0% | 25.9% |
Return vs Industry: ATAI underperformed the US Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: ATAI underperformed the US Market which returned 25.9% over the past year.
Price Volatility
| ATAI volatility | |
|---|---|
| ATAI Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ATAI's share price has been volatile over the past 3 months.
Volatility Over Time: ATAI's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 83 | Srini Rao | www.atai.life |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
Atai Life Sciences N.V. Fundamentals Summary
| ATAI fundamental statistics | |
|---|---|
| Market cap | US$219.82m |
| Earnings (TTM) | -US$58.07m |
| Revenue (TTM) | US$378.00k |
581.5x
P/S Ratio-3.8x
P/E RatioIs ATAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATAI income statement (TTM) | |
|---|---|
| Revenue | US$378.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$378.00k |
| Other Expenses | US$58.45m |
| Earnings | -US$58.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -15,362.70% |
| Debt/Equity Ratio | 12.4% |
How did ATAI perform over the long term?
See historical performance and comparison